Abbott Signs Ibogaine Research Bill; Cites Veterans as Potential Patients

June 12, 2025 – Texas Governor Greg Abbott signed a bill amassing $50 million to fund clinical trials of ibogaine, a psychedelic compound derived from the African iboga plant, under the federal BEACH Act–style framework. Though still a Schedule I controlled substance in the U.S., international studies have indicated its potential to reduce opioid withdrawal, treat PTSD, depression, and traumatic brain injuries—especially among veterans .

“Texas is home to more veterans than any other state,” said Governor Abbott. “Many of those veterans suffer from injuries both seen and unseen.

However, ibogaine carries serious health risks, most notably cardiac arrhythmias, with over 30 related fatalities reported. Supporters emphasize that careful patient screening and monitoring will be key as Texas steps into structured research.

Ibogaine is a psychoactive compound, a type of indole alkaloid, derived from the Tabernanthe iboga plant, primarily found in Central Africa. It’s known for its potential to induce hallucinogenic and oneirogenic experiences, which have led to its traditional use by certain African communities. Additionally, ibogaine has been researched, albeit controversially, for its potential in treating substance use disorders. 

Bill SB 2308 (and its House counterpart HB 3717) establishes a public–private partnership: state funds will be matched by private investment, emphasizing Texas’s commercial rights over resulting intellectual property The initiative prioritizes veterans and first responders, supported by figures like former Governor Rick Perry and Rep. Morgan Luttrell—both veterans advocating psychedelic therapies.

Currently, ibogaine remains illegal in Texas and nationwide, so Texans seeking treatment typically travel to clinics in Mexico or Canada. Advocates, including the Texas Emerging Therapies Association, are pushing the legislature to legalize controlled trials and build infrastructure for safe domestic access.